Skip to main content

Picodya is proud to announce our plans for a new state-of-the-art facility in Maryland. Our US facility will become fully operational as of January 2025. This expansion represents a significant step forward in our mission to transform diagnostics with our groundbreaking “Pico-Tech” platform, which delivers lab-quality results in real-time with unparalleled efficiency and flexibility. Our Maryland site will serve as a hub for innovation, enabling us to drive development and accelerate the delivery of advanced diagnostic solutions to healthcare providers worldwide.

Located close to the National Institute of Allergy and Infectious Diseases (NIAID), our new site strengthens our efforts to support our ongoing collaboration with NIAID and open the door for additional new leading institutions. This proximity will enhance our ability to provide innovative solutions that make diagnostics more accessible, precise, and efficient for the benefit of patients and healthcare systems globally.